Introduction
More than 4 years have passed since the gene responsible for Duchenne/Becker muscular dystrophy (DMD/BMD) was identified. Progress in understanding this gene and its role in disease has followed at a breathtaking pace, and the rapidly emerging information has been summarized in at least three reviews in the past year alone [l-3] . This article is intended to highlight only the most significant advances made in the past year, and focuses on three specific areas: developing efficient and cost-effective methods for diagnosis and carrier detection of DMD; understanding the role of the DMD gene product, dystrophin; and developing approaches to a treatment or cure for the disease. In the absence of a treatment, disease diagnosis and genetic counseling remain the most concrete example of how recent progress is of benefit to patients. The understanding of how defects in the dystrophin gene lead to various manifestations of the disease is critical for an understanding of the role played by dystrophin in various tissue types, which, in turn, is important for an intelligent approach to developing and implementing treatments for DMD.
Diagnosis of DMD
Deletion mutations account for the majority of all cases of DMD, but the enormous size of the locus (> 2.3 x 106b p ) h as prevented any simple assay of the integrity of the gene or even a detailed understanding of the gene structure. Den Dunnen et al. [4*] have reported a detailed analysis that has retined knowledge of the gene structure, particularly in the deletion-prone central region. Boyce et al. have localized and characterized the extreme 5' end of the locus, corresponding to the promoter region used predominantly in brain tissue [ 5*] . This additional knowledge of the gene structure is critical for DNA-based diagnosis of DMD. Two groups have reported refinements of tests for the detection of deletions using the polymerase chain reaction (PCR) [6-,?I. These assays can be used to scan for deletions in the gene, enabling direct detection of the majority of cases with a simple assay requiring one day to perform. Partial gene duplication mutations have been shown to account for an additional 5-10% of DMD cases, and knowledge of the gene structure has facilitated analysis of the effects of these mutations and their likely origin [8*].
Approximately 30% of DMD cases result from subtle mutations not readily detectable with current methodologies, and family studies involving these cases are performed using linkage analysis of polymorphic loci that both lie within and flank the dystrophin gene. PCR promises to greatly facilitate these assays, and is soon likely to be the only technique needed for the diagnosis of the vast majority of cases. Two groups have reported PCR assays that enable efficient haplotyping using highly informative microsatellite repeat markers at either end of the locus [9,10*]. The dystrophin gene has been shown to be a very recombinagenic locus, which increases the possibility of making an erroneous diagnosis based upon linkage analysis [ 11.1. The identification of additional microsatellite repeats throughout the central region of the gene now makes it possible to track these recombination events and to perform accurate haplotyping on most DMD families (J Chamberlain, P Clemens, CT Caskey, unpublished data).
Two groups have reported an exciting alternative to DNAbased diagnosis, whereby the dystrophin mRNA is amplified to allow assessment of its size, again using PCR [12*,13*]. These assays have the advantage of being able to detect most structural rearrangements of the gene in affected males as well as in many carrier females, but although they require nothing more than a blood sample, these tests are not as simple to perform as the DNA assays. Finally, tests that examine the integrity of the dystrophin protein directly have been refined, and antibodies can now be used to identify the size of a defective protein species produced in dystrophic muscle [14*] . This information can also be used to understand the severity of the disease in relation to particular mutations. [20-l was found to lack almost 50% of the dystrophin amino acid sequence, yet displayed a surprisingly mild phenotype. The ability to correlate domains of the protein that are essential or nonessential for proper functioning of dystrophin may facilitate the design of vectors for gene therapy (see below). Finally, whereas studies of the role of dystrophin have focused mainly upon skeletal muscle, Lidov et al.
[21**] identified the location of at least one isoform of dystrophin within brain tissue. The observed brain localization implies that dystrophin plays a unique role in nerve cells, and it will be important to determine which proteins are associated with dystrophin in non-muscle tissues.
Therapy for DMD Despite recent progress on many fronts, there is still no treatment or cure for DMD. At least two areas of study appear promising, and both aim at directly replacing the synthesis of dystrophin in affected tissues. Myoblast transplantation therapy has been extensively discussed as a method to provide skeletal muscle with normal dystrophin, and was the focus of an international conference in 1989 that brought together many leading muscle researchers. Although both myoblast and gene therapy are extremely experimental approaches for treating DMD, research in these areas is encouraging. Five years ago there was little reason to expect a quick breakthrough, and years of additional research certainly remain. In spite of this, however, continued study of the structure, function, and expression of the dystrophin gene, together with the development of approaches for dystrophin delivery to affected tissues, do raise hopes for the successful treatment of this devastating and relativety common genetic disease. 
